Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
1(25%)
Results Posted
300%(3 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_2
3
75%
Ph not_applicable
1
25%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Completed1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 23 (75.0%)
N/A1 (25.0%)

Trials by Status

completed125%
recruiting125%
terminated250%

Recent Activity

1 active trials
Showing 4 of 4
recruitingnot_applicable

mAnaging siCkle CELl disEase Through incReased AdopTion of hydroxyurEa in Nigeria

NCT06318143
completedphase_2

Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3

NCT02466516
terminatedphase_2

Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

NCT01672866
terminatedphase_2

Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH

NCT01672879

Clinical Trials (4)

Showing 4 of 4 trials
NCT06318143Not Applicable

mAnaging siCkle CELl disEase Through incReased AdopTion of hydroxyurEa in Nigeria

Recruiting
NCT02466516Phase 2

Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3

Completed
NCT01672866Phase 2

Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Terminated
NCT01672879Phase 2

Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH

Terminated

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4